THE IMPACT OF LONG-TERM THERAPY BY A MULTIDISCIPLINARY TEAM ON THE EDUCATION, OCCUPATION AND MARITAL STATUS OF GROWTH HORMONE DEFICIENT PATIENTS AFTER TERMINATION OF THERAPY

1987 ◽  
Vol 27 (2) ◽  
pp. 191-196 ◽  
Author(s):  
A. GALATZER ◽  
O. ARAN ◽  
N. BEIT-HALACHMI ◽  
E. NOFAR ◽  
J. RUBITCHEK ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Marital Status ◽  
Multidisciplinary Team ◽  
Term Therapy ◽  
Long Term Therapy ◽  
The Impact

Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients

1993 ◽  
Vol 129 (3) ◽  
pp. 207-212 ◽  
Author(s):  
Yi-Fan Shi ◽  
Xian-Feng Zhu ◽  
Alan G Harris ◽  
Jin-Xi Zhang ◽  
Jie-Ying Deng
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Term Therapy ◽  
Serum Growth Hormone ◽  
Factor I ◽  
Gallbladder Contractility ◽  
Octreotide Therapy ◽  
Long Term Therapy ◽  
Growth Hormone Suppression

We sought to examine how the discontinuation of octreotide in long-term octreotide-treated acromegalic patients affects the well-documented side-effect of cholelithiasis. In 14 acromegalic patients, serum growth hormone levels, insulin-like growth factor I levels and percentage of relative gallbladder contractility were measured prior to and after the discontinuation of octreotide. Compared to pretreatment values, the basal growth hormone and 5-h growth hormone profiles were 36% and 24%, and 60% and 56% at the end of 1 and 2 weeks, respectively. Octreotide was found to be eliminated completely from the serum within 3 days after its withdrawal. In all of six patients who did not develop gallstones, the percentage relative gallbladder contractility normalized within 1 week. In eight patients who developed gallstones, four of them had restoration of normal contractility within 2 weeks. Our results show that upon withdrawal of octreotide, gallbladder contractility returns to normal while growth hormone suppression persists for a longer period of time. Therefore, discontinuation of octreotide therapy may allow for the clearance of stagnated bile and hence decrease the incidence of cholelithiasis in acromegalic patients receiving long-term therapy.

scholarly journals What is the impact of methotrexate on liver in patients with juvenile idiopathic arthritis? Results of liver SWE performed in a single centre

2021 ◽  
Author(s):  
Vildan Güngörer ◽  
Mehmet Öztürk ◽  
Mustafa Yasir Özlü ◽  
Şükrü Arslan
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Shear Wave Elastography ◽  
Term Therapy ◽  
Control Group ◽  
Significant Difference ◽  
Group 2 ◽  
Long Term Therapy ◽  
And Control ◽  
The Impact

ABSTRACT Objectives Long-term therapy with low-dose methotrexate (MTX) is widely used in treatment of rheumatic diseases, in children. The purpose of this study was to evaluate liver elasticity in patients with juvenile idiopathic arthritis (JIA) who received MTX and compare the results with control group. Methods Liver elasticity was evaluated with shear wave elastography (SWE) technique in 25 patients aged 3–17 years who were followed up with JIA and received MTX and compared with 25 healthy controls of the same age and weight. Factors that had an effect on liver elasticity were examined. Results The mean SWE value of patients was 2.64 ± 2.13 m/s and 24.10 ± 18.50 kPa, whereas 1.83 ± 0.16 m/s and 10.09 ± 1.83 kPa in control group. There was a significant difference in liver elasticity in the patient and control groups. When the patients were evaluated as Group 1 (< 1000 mg) and Group 2 (≥ 1000 mg) according to the cumulative MTX dose, no significant difference was obtained. There was positive correlation between liver elasticity and weekly MTX dose and age. Conclusions Our study revealed that liver elasticity significantly decreased in patients who received MTX when compared with the control group. The elastography technique will be understood better over time and used safely in many areas.

Good response to long-term therapy with growth hormone in a patient with 9p trisomy syndrome: A case report and review of the literature

2015 ◽  
Vol 170 (4) ◽  
pp. 1046-1049 ◽  
Author(s):  
Ana Pinheiro Machado Canton ◽  
Mirian Yumie Nishi ◽  
Tatiane Katsue Furuya ◽  
Rosimeire Aparecida Roela ◽  
Alexander Augusto Lima Jorge
Keyword(s):  
Growth Hormone ◽  
Case Report ◽  
Term Therapy ◽  
Review Of The Literature ◽  
Long Term Therapy

scholarly journals Central, peripheral, and renal hemodynamics in patients with hypertensive disease during long-term monotherapy with enalapril alone and in combination with hydrochlorothiazide (according to the data of RU-003 study)

2004 ◽  
Vol 10 (1) ◽  
pp. 19-22
Author(s):  
A. O. Konradi ◽  
R. Kh. Afaunov ◽  
O. V. Mamontov ◽  
A. A. Pushkarev ◽  
A. N. Krutikov ◽  
...  
Keyword(s):  
Time Course ◽  
Combined Therapy ◽  
Blood Flow Rate ◽  
Renal Hemodynamics ◽  
Term Therapy ◽  
Hypertensive Disease ◽  
The Status ◽  
Long Term Therapy ◽  
The Impact

The study was undertaken to examine the impact of long-term therapy with enapril alone and in its fixed combination with hydrochlorothiazide (renitec/co-renitec, MSD) on the time course of changes in central, peripheral, and renal hemodynamic parameters and on the status of cardiopulmonary reflex in patients with hypertensive disease. The study included 35 patients with Stages I-II arterial hypertension. Therapy with renitec/co-renitec was performed for 6 months, starting with its dose of 10 mg, followed by titration up to 40 mg and switching to a combined therapy. A decrease in blood pressure in the groups of patients receiving therapy with enalapril alone and in combination with hydrochlorothiazide was found to be associa ted mainly with diminished peripheral vascular resistance, which was followed by a higher volume blood flow rate in the forearm-and a better sensitivity of the cardiopulmonary baroreflex. Moreover, long-term use of enalapril both alone and in combination with thiazide diuretic was attended by improved renal hemodynamics.

scholarly journals Effects of Growth Hormone on Craniofacial Growth

2006 ◽  
Vol 76 (6) ◽  
pp. 970-977 ◽  
Author(s):  
Minayo Funatsu ◽  
Koshi Sato ◽  
Hideo Mitani
Keyword(s):  
Growth Hormone ◽  
Therapy Group ◽  
Untreated Group ◽  
Term Therapy ◽  
Craniofacial Growth ◽  
Gh Therapy ◽  
Facial Height ◽  
Long Term Therapy ◽  
Ramus Height

Abstract Objective: This study determined the effects of growth hormone (GH) therapy on craniofacial growth in idiopathic growth hormone deficiency (GHD). Materials and Methods: Fifty-seven patients (33 boys and 24 girls; age range 4.5 to 16.7 years) with GHD were investigated and categorized into three groups according to the duration of GH therapy: the untreated group, the short-term therapy group, and the long-term therapy group. Their lateral cephalometric radiographs were studied, and craniofacial measurements were assessed by age and sex by using matched standard deviation scores. Results: In the untreated group, the anterior cranial base, total facial height, maxillary length, mandibular total length, mandibular body length, and ramus height were smaller than the standard values. In comparison with the untreated group, the long-term therapy group had a significantly larger upper facial height (P < .05), maxillary length (P < .01), and ramus height (P < .01) measurements. Conclusions: Children who received long-term GH replacement therapy showed increased growth of the craniofacial skeleton, especially the maxilla and ramus. These findings suggest that GH accelerates craniofacial development, which improves occlusion and the facial profile.

Long-term growth hormone treatment in growth hormone deficient adults

1991 ◽  
Vol 125 (4) ◽  
pp. 449-453 ◽  
Author(s):  
Jens O. L. Jørgensen ◽  
Søren A. Pedersen ◽  
Leif Thuesen ◽  
Jørgen Jørgensen ◽  
Jens Møller ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Treatment ◽  
Normal Subjects ◽  
Hormone Treatment ◽  
Long Term Results ◽  
Term Therapy ◽  
Gh Therapy ◽  
Double Blind ◽  
Long Term Therapy

Abstract. Growth hormone treatment in GH-deficient adults has proved beneficial in recent short-term trials, but long-term results have not yet been reported. Thirteen GH-deficient adults (4 females, 9 males; mean (sem) age 26.4 (1.7) years), who had completed 4 months of GH therapy in a double-blind placebo-controlled cross-over study were followed, for further 16.1 (0.8) months of uninterrupted GH therapy in an open design. A significant mean increase of 1.3 cm in linear height was recorded, whereas body mass index remained unchanged. Mean muscle volume of the thigh, estimated by computerised tomography, increased significantly compared with that of the initial placebo period (p=0.01), and a slight decrease was recorded in adipose tissue volume of the thigh (p=0.10) and subscapular skinfold thickness (p=0.10). Still, the muscle to fat ratio of the thigh was significantly lower compared with that of normal subjects (72.6/27.4 vs 77.9/22.1) (p<0.01). The mean isometric strength of the quadriceps muscles increased significantly during long-term GH therapy (p<0.01), but remained lower compared with that of normal subjects (1.66 (0.10) vs 2.13 (0.11) Nm/kg body weight). Exercise capacity performed on a bicycle ergometer increased significantly after long-term therapy (p<0.05), but still did not reach the values seen in normal subjects (22.5 (3.4) vs 37.4 (4.2) watt · min · kg−1· No adverse reactions were recorded during long-term therapy and hemoglobin A1c remained unchanged. These data suggest that long-term GH replacement therapy in GH-deficient adults has beneficial effects on several physiological features which are subnormal in these patients.

Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon-α

2007 ◽  
Vol 102 (12) ◽  
pp. 2724-2731 ◽  
Author(s):  
Ursula Plöckinger ◽  
Denny Krüger ◽  
Alexandra Bergk ◽  
Viola Weich ◽  
Bertram Wiedenmann ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Term Therapy ◽  
Interferon Α ◽  
Gh Secretion ◽  
Long Term Therapy

scholarly journals The role of diuretics in the treatment of hypertension: a focus on chlorthalidone (lecture)

HYPERTENSION ◽  
2021 ◽  
Vol 14 (2) ◽  
pp. 12-29
Author(s):  
Yu.M. Sirenko
Keyword(s):  
Cardiovascular Complications ◽  
Term Therapy ◽  
Thiazide Diuretics ◽  
Cerebrovascular Complications ◽  
Hypertension Therapy ◽  
Long Term Therapy ◽  
The Impact ◽  
Therapy Of Hypertension

The lecture discusses the role of thiazide and thiazide-like diuretics, in particular chlorthalidone, in the modern treatment of arterial hypertension. The modern concepts about the mechanism of action of thiazide diuretics and chlorthalidone are presented. Differences in the degree of antihypertensive effect of hydrochlorothiazide and chlorthalidone are discussed. The results of large randomized trials SHEP, MRFIT, ALLHAT were analyzed, in which chlorthalidone therapy significantly reduced the risk of developing cardiovascular and cerebrovascular complications of hypertension. The effect of thiazide diuretics on glucose metabolism and the impact of carbohydrate metabolism disorders during treatment with chlorthalidone on the risk of cardiovascular complications was considered. The lecture also discusses the effect of chlorthalidone therapy on kidney function, the possibility of its use in chronic kidney disease. The data are presented on the prevention of resistant hypertension and chro-nic heart failure during long-term therapy of hypertension with chlorthalidone. The frequency and terms of the development of side effects of hypertension therapy with thiazide-like diuretics were also analyzed.

Sign in / Sign up

Export Citation Format

Share Document